<table name="logo_release" border="0" cellspacing="10" cellpadding="5" align="right">   <tbody>    <tr>     <td><img src="https://mma.prnasia.com/media2/2757286/NEO_Logo.jpg?p=medium600" border="0" alt="" title="logo" hspace="0" vspace="0" width="118" /></td>    </tr>   </tbody>  </table>  <p><i>Partnership delivers tamper-evident, high-integrity testing data aligned with U.S. Drug Policy Priorities</i></p>  <p><span class="legendSpanClass"><span class="xn-location">WASHINGTON</span></span>, <span class="legendSpanClass"><span class="xn-chron">Aug. 26, 2025</span></span> /PRNewswire/ -- Neopharma Technologies Limited (&quot;Neopharma&quot;) today announced it has <b>entered into a global software licensing and collaboration agreement</b> with Zhejiang Orient Gene Biotech Co., Ltd. (&quot;Orient Gene&quot;) to integrate Neopharma's NEOVAULT&reg; software across Orient Gene's range of Drugs of Abuse (DOA) rapid tests under the Healgen&reg; brand.</p>  <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">   <p> </p>  </div>  <p><b>Why This Matters</b></p>  <p>The partnership combines <b>proven rapid drug testing hardware</b> with <b>NEOVAULT&reg;'s digital intelligence</b>, delivering:</p>  <ul type="disc">   <li><b>Tamper-evident capture of results</b> at the point of testing, with automated audit trails for safety-critical environments.</li>   <li><b>Instant, de-identified analytics</b>&nbsp;to reveal trends by site, shift, and risk factor?봢nabling earlier, targeted interventions.</li>   <li><b>Built-in interoperability</b> so results flow securely into HR and clinical systems for prevention, compliance, and reporting.</li>  </ul>  <p><b>Alignment with U.S. Drug Policy Priorities</b></p>  <p>This collaboration aligns with priorities highlighted by the White House Office of National Drug Control Policy's <span class="xn-chron">April 1, 2025</span> statement:</p>  <ul type="disc">   <li><b>Priority 1 ??Reduce Overdose Fatalities (fentanyl focus):</b>&nbsp;NEOVAULT&reg; digitizes screening results and can flag fentanyl rapid test results in real time, producing live 'heat maps' for U.S. authorities.</li>   <li><b>Priority 6 ??Innovate in Research and Data:</b>&nbsp;NEOVAULT&reg; generates accurate, shareable, and timely data for rigorous analytics and secure information exchange. This supports modernization of the DOA testing industry?봡igitizing workflows and harnessing AI/ML alongside public-private partnerships to address emerging threats.</li>  </ul>  <p><b>Security &amp; Compliance</b></p>  <p>NEOVAULT&reg; is designed to meet the highest security and privacy standards, including:</p>  <ul type="disc">   <li>ISO 27001 international certification for information security management</li>   <li>SOC 2 Type II attestation across all Trust Services Criteria</li>   <li>HIPAA U.S. certification for handling, storing, and transmitting protected health information</li>   <li>GDPR-aligned controls supporting covered entities, business associates, and EU/UK data processors</li>  </ul>  <p><b>Executive Commentary</b></p>  <p><b>Marcus L'Estrange, Executive Chairman, Neopharma Technologies:</b></p>  <p>&quot;We are raising the global standard for digital drug testing. By enabling Healgen&reg;'s extensive DOA portfolio with NEOVAULT&reg;, we transform paper-based results into structured intelligence?봦elping employers act faster and giving policymakers real-time insights.&quot;</p>  <p><b><span class="xn-person">Byran Fang</span>, President, Orient Gene:</b></p>  <p>&quot;As a global leader in the field of In-Vitro Diagnostics, Orient Gene is committed to advancing both the accuracy and accessibility of rapid testing. This partnership ensures our customers benefit from the trusted performance of&nbsp;Healgen&reg; devices and the added value of secure, real-time digital reporting.&quot;</p>  <p><b>What Customers Will Get</b></p>  <ul type="disc">   <li><b>NEOVAULT&reg;-enabled Healgen&reg; test devices:</b> Same simple workflow, now with guided capture, scannable kit IDs, and real-time reporting of results.</li>   <li><b>NEOVAULT&reg; ERM platform:</b> A highly secure system for Third Party Administrators and Drug Testing businesses to create digital reports in the field with ease. It also provides HR teams with real-time data to support hiring decisions in minutes, compared to the typical 4?? day timeframe.</li>   <li><b>Enterprise connectors:</b> API integrations with common HRIS platforms and role-based access controls.</li>  </ul>  <p><b>About Orient Gene /&nbsp;Healgen&reg;</b></p>  <p>Orient Gene's Healgen&reg; brand delivers widely used rapid in-vitro diagnostic devices, including multi-panel cups, cassettes, and strips for DOA screening.</p>  <p><b>About Neopharma Technologies Limited</b></p>  <p>Neopharma Technologies is an Australian health-technology company focused on digital drug and impairment testing to create safer workplaces globally. Its mission is for <b>NEOVAULT&reg;</b> to become the world's default digital testing platform for point-of-care.</p>  <p><b>Trademarks:</b>&nbsp;NEOVAULT&reg; is a registered trademark of Neopharma Technologies Limited. Healgen&reg; is a registered brand of Orient Gene.<br /><b>Policy reference:</b> White House, Office of National Drug Control Policy, <i>Statement of Drug Policy Priorities</i> (<span class="xn-chron">April 1, 2025</span>).</p>